Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Share-based Compensation (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Share-based Compensation for 3 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 48.94% to $14.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.4 million through Dec 2025, up 76.76% year-over-year, with the annual reading at $59.4 million for FY2025, 76.76% up from the prior year.
  • Share-based Compensation hit $14.0 million in Q4 2025 for NewAmsterdam Pharma, down from $15.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $15.2 million in Q1 2025 to a low of $5.4 million in Q3 2023.
  • Historically, Share-based Compensation has averaged $9.8 million across 3 years, with a median of $8.1 million in 2024.
  • Biggest five-year swings in Share-based Compensation: rose 3.97% in 2024 and later skyrocketed 92.13% in 2025.
  • Year by year, Share-based Compensation stood at $6.0 million in 2023, then soared by 56.76% to $9.4 million in 2024, then surged by 48.94% to $14.0 million in 2025.
  • Business Quant data shows Share-based Compensation for NAMS at $14.0 million in Q4 2025, $15.0 million in Q3 2025, and $15.2 million in Q2 2025.